Headspace analysis of mesothelioma cell lines differentiates biphasic and epithelioid sub-types. by Little, Liam David et al.
Headspace analysis of mesothelioma cell lines 
differentiates biphasic and epithelioid sub-types.
LITTLE, Liam David <http://orcid.org/0000-0001-8681-4133>, CAROLAN, 
Vikki Amanda, ALLEN, K Elizabeth, COLE, Laura Margaret and HAYWOOD-
SMALL, Sarah Louise <http://orcid.org/0000-0002-8374-9783>
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/26917/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
LITTLE, Liam David, CAROLAN, Vikki Amanda, ALLEN, K Elizabeth, COLE, Laura 
Margaret and HAYWOOD-SMALL, Sarah Louise (2020). Headspace analysis of 
mesothelioma cell lines differentiates biphasic and epithelioid sub-types. Journal of 
Breath Research. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
Journal of Breath Research
ACCEPTED MANUSCRIPT • OPEN ACCESS
Headspace analysis of mesothelioma cell lines differentiates biphasic
and epithelioid sub-types
To cite this article before publication: Liam David Little et al 2020 J. Breath Res. in press https://doi.org/10.1088/1752-7163/abaaff
Manuscript version: Accepted Manuscript
Accepted Manuscript is “the version of the article accepted for publication including all changes made as a result of the peer review process,
and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an ‘Accepted
Manuscript’ watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors”
This Accepted Manuscript is © 2020 IOP Publishing Ltd.
 
As the Version of Record of this article is going to be / has been published on a gold open access basis under a CC BY 3.0 licence, this Accepted
Manuscript is available for reuse under a CC BY 3.0 licence immediately.
Everyone is permitted to use all or part of the original content in this article, provided that they adhere to all the terms of the licence
https://creativecommons.org/licences/by/3.0
Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content
within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this
article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions may be required.
All third party content is fully copyright protected and is not published on a gold open access basis under a CC BY licence, unless that is
specifically stated in the figure caption in the Version of Record.
View the article online for updates and enhancements.
This content was downloaded from IP address 86.178.194.190 on 10/08/2020 at 14:07
IOP Publishing Journal Title
Journal XX (XXXX) XXXXXX https://doi.org/XXXX/XXXX
xxxx-xxxx/xx/xxxxxx 1 © xxxx IOP Publishing Ltd
Headspace Analysis of Mesothelioma Cell Lines 
Differentiates Biphasic and Epithelioid Sub-Types.
Liam David Little, Vikki Amanda Carolan, K Elizabeth Allen, Laura Margaret Cole & Sarah 
Louise Haywood-Small
 Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, United Kingdom
E-mail: s.haywood-small@shu.ac.uk
Received xxxxxx
Accepted for publication xxxxxx
Published xxxxxx
Abstract
Malignant mesothelioma (MM) is an incurable cancer. MM is often misdiagnosed, with a poor 5-year survival and limited 
treatment options. The discovery of endogenous volatile organic compounds (VOCs) is required in order to accelerate the 
development of a breath test as an alternative to conventional MM diagnosis. For the first time, this study used solid-phase 
microextraction (SPME) and gas chromatography-mass spectrometry (GC-MS) to identify VOCs released directly from the 
biphasic MM cell line MSTO-211H and the epithelioid MM cell line NCI-H28 as well as the non-malignant mesothelial cell 
line MET-5A. Multivariate statistical analysis showed separation between MSTO-211H, NCI-H28 and MET-5A results. 2-
ethyl-1-hexanol was significantly increased in both MSTO-211H and NCI-H28 cells compared to MET-5A controls. In 
addition, ethyl propionate and cyclohexanol were significantly increased in MSTO-211H cells and dodecane was significantly 
increased in NCI-H28 cells. This is the first study reporting headspace analysis of these MM cell lines and the first to consider 
the effects of mesothelioma sub-type on VOC profile. Current results further highlight the potential for a diagnostic 
mesothelioma breath test as well as providing proof of concept for the differentiation between biphasic and epithelioid 
mesothelioma based on VOC profiles. 
Keywords: malignant mesothelioma, volatile organic compounds, headspace analysis
1. Introduction
Malignant mesothelioma (MM) is an extremely aggressive 
and incurable malignancy most commonly affecting the 
mesothelial cell lining of the pleura as well as other internal 
organs [1]. MM has a long-established causative link to 
asbestos exposure [2], a group of naturally occurring silicate 
mineral fibres that were widely used in UK manufacturing 
industries [3]. Despite the regulation of asbestos which was 
introduced in the mid-1980's, UK MM incidence has risen in 
that time due to a prolonged latency period of up to 60 years 
since initial exposure [4]. As well as this, approximately 80% 
of the global population live in countries without strict 
asbestos controls [1, 3], meaning that MM will be a worldwide 
public health issue for many years to come. In order to 
improve survival and treatment options, an increased number 
of patients - particularly at an early stage - must be identified 
to enrol onto clinical trials and allow for long-term monitoring 
of disease progression [5]. 
Currently MM diagnosis is ineffective; patients are often 
diagnosed at a very late stage leading to a poor prognosis of 
just 12-14 months following combined pemetrexed and 
platinum palliative therapy [6]. It is difficult to identify 
patients at an early stage due to the prolonged latency period 
and non-specific signs and symptoms such as chest pains and 
pleural effusions, which present only in the late stages of the 
disease [7]. MM tumours can often be mistaken for lung 
carcinomas and can be classified into epithelioid, sarcomatoid 
and biphasic sub-types, with differing prognoses [3]. 
Definitive MM diagnosis must be confirmed through a chest 
CT scan and invasive biopsies [8]. These issues highlight the 
requirement of a novel diagnostic method within MM; one 
capable of identifying patients at an earlier disease stage, 
differentiating between MM sub-types and avoiding invasive 
biopsy procedures. 
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Proteins, such as mesothelin, derived from blood and 
pleural effusions have been investigated as potential MM 
biomarkers but have failed to translate clinically due to a lack 
of sensitivity [9]. An alternative to protein biomarkers is the 
analysis of volatile organic compounds (VOCs) in exhaled 
breath, which has gained traction within disease diagnosis and 
monitoring [10]. Previous studies have used gas 
chromatography-mass spectrometry (GC-MS) to identify 
VOCs in MM patient breath samples, showing that VOC 
patterns could discriminate between MM patients and other 
clinical groups [11, 12, 13]. These initial studies provided 
evidence for the identification of MM patients based on a 
distinct profile of VOCs in exhaled breath - suggesting that it 
may be possible to diagnose mesothelioma non-invasively 
through a VOC-based breath test.
The use of VOC analysis within more well understood 
cancers, such as lung cancer, has seen further development 
than in MM. As such, previous studies have analysed the 
headspace gas above lung cancer cell lines as a model for 
patient breath analysis [14]. The use of in vitro cell lines 
allows for the exploration of the origins of VOC release 
through controlled molecular biology experiments targeting 
specific processes. These types of studies have assessed the 
impact of oxidative stress [15] and genetic mutations [16] on 
VOC output, something that would not be possible using 
patient-derived breath samples. To date there have been no 
such studies in MM - a cancer that is much rarer and less well 
understood than lung cancer, which therefore requires in vitro 
models in order to fully research it. Mesothelioma is also a 
cancer that stands to benefit greatly from VOC analysis due to 
the current issues faced with diagnosis and extremely poor 5-
year survival rate [1]. Therefore, an in vitro model of MM 
VOC analysis would be a valuable tool in understanding this 
cancer and progressing towards a VOC-based diagnostic test.
For the first time, this study applied VOC analysis methods 
to a panel of mesothelioma cell lines. The cell lines were 
chosen to explore the differences in VOC production from 
biphasic and epithelioid MM sub-types, potentially using 
headspace to differentiate between these two groups. Biphasic 
mesotheliomas contain both epithelioid and sarcomatoid 
morphologies and are associated with a worse prognosis than 
the epithelioid sub-type alone [3]. Prognosis becomes even 
poorer as the percentage of sarcomatoid cells increases [3]. It 
is difficult to distinguish between MM sub-types with current 
methods meaning that patients are often mis-diagnosed [8]. 
MSTO-211H was used as a biphasic MM cell line and NCI-
H28 as an epithelioid morphology - both cell lines are derived 
from metastatic pleural effusion [17]. These compounds were 
compared to a non-malignant mesothelial cell line control, 
MET-5A, in order to discover VOCs specifically associated 
with MM. Solid-phase microextraction (SPME) followed by 
gas chromatography-mass spectrometry (GC-MS) was used to 
analyse the headspace gas above MSTO-211H, NCI-H28 and 
MET-5A cell cultures, identifying VOCs released by the cells 
to establish a working model of MM VOC analysis. 
2. Materials & Methods
All reagents and materials were purchased from Sigma 
Aldrich (Gillingham, UK) unless otherwise stated.
2.1 Cell Culture
MSTO-211H, NCI-H28 and MET-5A cell lines were 
purchased from American Type Culture Collection (ATCC). 
MSTO-211H and NCI-H28 cells were maintained in RPMI-
1640 (Thermo Fisher; Loughborough, UK) supplemented 
with a final concentration of 10% volume/volume (v/v) foetal 
bovine serum (FBS) and 1% v/v penicillin/streptomycin. 
MET-5A cells were maintained in medium 199 with 10% v/v 
FBS, 1% v/v penicillin/streptomycin, 3.3nM epidermal 
growth factor (Fisher Scientific; Loughborough, UK), 400nM 
hydrocortisone, 870nM zinc-free bovine insulin, 20mM 
HEPES and 0.3% v/v Trace Elements B (VWR; Lutterworth, 
UK). All three cell lines were maintained at 37oC in the 
presence of 5% CO2 in air in a humidified incubator. Culture 
medium was replaced every 2-3 days and cells sub-cultured 
through Trypsin-EDTA (Thermo Fisher; Loughborough, UK) 
detachment when reaching 70-80% confluence. All cell lines 
passed routine mycoplasma testing. 
2.2 Experimental Design
MSTO-211H, NCI-H28 and MET-5A cell cultures were 
prepared for headspace analysis - all cell cultures were under 
passage number 25. 1.8x106 cells were seeded in standard T75 
cell culture flasks and incubated at 37oC with 5% CO2 for 72 
hours. Control flasks containing complete RPMI-1640 and 
medium 199 only were also prepared and incubated at 37oC 
with 5% CO2 for 72 hours. Control flasks were used to deduct 
background signals, caused by cell culture media, from the 
cell line profiles. After incubation, VOCs were extracted from 
the headspace gas of cell culture and control flasks and 
analysed using GC-MS. 
2.2.1 VOC Extraction
MSTO-211H, NCI-H28 and MET-5A cell confluence was 
recorded prior to VOC extraction. A 50/30µm 
divinylbenzene/Carboxen/polydimethylsiloxane 
(DVB/CAR/PDMS) SPME fibre (Supelco; Gillingham, UK) 
was used to extract VOCs from the headspace gas above 
MSTO-211H, NCI-H28 and MET-5A cell cultures and RPMI-
1640 and medium 199 controls. A new SPME fibre was 
conditioned in the inlet of a GC-MS at 270oC for 30 minutes 
according to manufacturer's instructions prior to initial use and 
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cleaned for 10 minutes in the inlet of a GC-MS at 250oC to 
remove residual compounds before VOC extraction. For VOC 
extraction, the SPME fibre assembly was inserted directly 
through the filter cap of cell culture and control flasks and the 
fibre exposed to the headspace for 15 minutes. VOC extraction 
was performed at 37oC with 5% CO2. After VOC extraction, 
MSTO-211H, NCI-H28 and MET-5A cell number and 
viability was assessed via Trypan-Blue exclusion using a 
Countess automated cell counting device (Invitrogen; 
Loughborough, UK). 
2.2.2 Gas Chromatography-Mass Spectrometry
An Agilent 7890A with a Rtx-VMS capillary column (30m 
x 0.25mm x 1.4µm; Restek; Saunderton, UK) and a MS-
5975C triple axis detector was used for VOC analysis. The 
GC-MS inlet temperature was set to 250oC. The oven 
temperature programming was as follows: 35oC held for 5 
minutes, ramped to 140oC at 4oC/min and held for 5 minutes, 
ramped again to 240oC at 20oC/min and held for 4 minutes. 
The total run time was 45.25 minutes. The MS transfer line 
was set to 260oC and VOC analysis was performed in full scan 
mode with a range of 35-300 a.m.u. Extracted VOCs were 
analysed through manual direct injection into the inlet of the 
GC-MS. The SPME fibre assembly was injected into the inlet 
of the GC-MS and the fibre was exposed for 10 minutes at the 
start of the oven temperature program to release VOCs and 
clean SPME fibre for further extractions. 
2.2.3 Data Analysis
Compounds were tentatively identified through mass 
spectral match to the NIST library database (National Institute 
of Health; V11). A pairwise analysis was performed in XCMS 
online (The Scripps Research Institute) to remove culture 
media background signals from cell line profiles. RPMI-1640 
signals were deducted from MSTO-211H and NCI-H28 
profiles and medium 199 signals were deducted from MET-
5A profiles. Culture media background signals and signals 
from siloxane compounds were removed from further 
analysis. Principal component analysis (PCA) and orthogonal 
partial least squares-discriminant analysis (OPLS) were 
performed on MSTO-211H, NCI-H28 and MET-5A results 
using OpenChrom® [18]. T-tests were performed within 
XCMS online to compare the cell line groups, identifying 
significantly altered VOCs in MSTO-211H and NCI-H28 with 
comparison to the MET-5A group that also had a ≥80% 
spectral match to the NIST library database.
3. Results
3.1 Cell Viability After VOC Extraction
Cell viability was assessed to determine the effects of 
headspace SPME on cell cultures. Differences in the number 
of viable cells assessed from MSTO-211H, NCI-H28 and 
MET-5A cultures after VOC extraction was observed (Fig. 1). 
In contrast to this the number of viable cells as a percentage 
of total cells was at a consistently high level across MSTO-
211H, NCI-H28 and MET-5A cultures (Fig. 1). 
Figure 1. Cell number and percentage viability of MSTO-211H, 
NCI-H28 & MET-5A cell cultures after VOC extraction measured 
through Trypan-Blue exclusion. 6 replicates of each cell line were 
measured (data represent mean ± standard deviation)
3.2 VOC Profiles
Initial headspace analysis showed approximately 100-200 
compounds in each MSTO-211H, NCI-H28 and MET-5A 
flask (Fig. 2). Chromatograms produced from SPME GC-MS 
of MSTO-211H, NCI-H28 and MET-5A groups appeared 
very similar, making it difficult to identify any observable 
differences in VOCs (Fig. 2). 
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Figure 2. Exemplary GC-MS chromatograms showing VOC profiles of MSTO-211H, NCI-H28 and MET-5A cell culture headspace after 
72 hours incubation
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3.3 Statistical Analysis
Statistical analysis was performed to determine if there 
were differences between the groups. PCA was used to 
visualise the trends between the MSTO-211H, NCI-H28 and 
MET-5A groups, which were then further classified with 
OPLS. T-tests were performed in XCMS online to identify 
significantly different VOCs in the MSTO-211H and NCI-
H28 groups with comparison to the MET-5A group. 
3.3.1 PCA & OPLS Score Plots
Background culture media signals and signals from 
siloxane compounds were removed from analysis (Table S1-
S3). Despite some overlapping results, some separation was 
observed between MSTO-211H, NCI-H28 and MET-5A 
groups using PCA (Fig. 3). When further classifying these 
results with OPLS, MSTO-211H and NCI-H28 groups were 
clearly separated from MET-5A results and MSTO-211H and 
NCI-H28 groups were distinct from each other (Fig. 3).  
3.3.2 Mesothelioma Specific VOCs.
MSTO-211H and NCI-H28 specific VOCs were compared 
to MET-5A specific VOCs. Significant differences in several 
compounds were observed in the MSTO-211H and NCI-H28 
groups with comparison to the MET-5A group (Table 1). 2-
ethyl-1-hexanol was significantly increased in both the 
MSTO-211H and NCI-H28 groups compared to the MET-5A 
group (Table 1). In addition, ethyl propionate and 
cyclohexanol were significantly increased in MSTO-211H 
cells and dodecane was significantly increased in NCI-H28 
cells (Table 1).
Figure 3. PCA and OPLS score plots of MSTO-211H, NCI-H28 and MET-5A results
Table 1. Significantly altered VOCs in MSTO-211H and NCI-H28 groups with comparison to the MET-5A group that also had a ≥80% 
spectral match to the NIST library database.
Average RT (min) Compound Trend MSTO-211H p-value Trend NCI-H28 p-value
11.6 Ethyl propionate ↑ <0.01 - -
20.8 Cyclohexanol ↑ <0.01 - -
26.6 2-ethyl-1-hexanol ↑ <0.01 ↑ 0.01
30.0 Dodecane - - ↑ <0.01
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 4. Discussion
There is an urgent need to develop new diagnostic methods 
for MM; new approaches should be capable of identifying 
patients at an earlier disease stage, differentiating between 
MM sub-types and avoiding invasive biopsy procedures. 
Previous studies have explored breath analysis within 
mesothelioma. The current study applied VOC analysis to 
mesothelioma cell lines, identifying compounds in vitro and 
providing a model for the further study of mesothelioma. This 
is the first step in the development of in vitro VOC analysis 
within mesothelioma. Controlled in vitro studies such as this 
are useful to compare compounds found in patient breath and 
subsequently explore the biological origins of VOC 
production. Two MM cell lines; biphasic MSTO-211H and 
epithelioid NCI-H28; and the non-malignant mesothelial 
MET-5A were analysed, allowing for comparison between 
mesothelioma sub-types. 
A change in metabolism during cell death and apoptosis has 
the potential to influence VOC profiles. The high viability of 
the cultures (Fig. 1) suggests that the cells did not undergo 
detrimental levels of cell death and apoptosis during the 72 
hour incubation time. Combined with the deduction of culture 
media background signals, it is therefore likely that the 
changes in VOCs observed between the three groups was 
caused by the different cell lines. Changes in cell number were 
also observed (Fig. 1), which was expected due to differences 
in size, morphology and growth rate between the three 
authenticated cell lines.  
Previously,  a number of VOCs identified in breath were 
used to discriminate samples obtained from MM patients to 
those those of healthy controls, as well as other clinical groups 
[11, 12, 13]. The current study used a panel of cell lines to act 
as a model for MM VOC analysis. MSTO-211H cells 
represented biphasic MM, NCI-H28 is considered to be 
epithelioid MM and MET-5A was selected as a non-malignant 
mesothelial cell type. Multivariate analysis revealed that the 
three cell lines produced distinct headspace VOC profiles 
(Fig. 3). The current results recapitulate that which has 
previously been reported in vivo - confirming that MM cells 
themselves produce a different VOC profile to that of non-
malignant cells and showing that MM cell lines can act as a 
viable model for VOC analysis.  
Mesothelioma tumours can consist of different cell 
morphologies producing the distinct clinical sub-types: 
epithelioid, sarcomatoid and biphasic MM [3]. Sarcomatoid 
MM has a worse prognosis than epithelioid, whilst biphasic 
mesotheliomas contain a combination of both cell types, with 
prognosis becoming increasingly poorer depending upon the 
percentage of sarcomatoid cells present [3]. At present, it is 
difficult to differentiate between MM sub-types at diagnosis 
meaning that patient stratification is not currently in clinical 
practice [3]. As well as this, previous MM breath analysis 
studies did not consider the impact of tumour sub-type on 
patient VOC profiles [11, 12, 13]. MSTO-211H and NCI-H28 
VOC profiles were distinct enough to show separation 
between the two cell lines (Fig. 3) and compounds were 
identified that were specifically increased in either the MSTO-
211H or NCI-H28 group with comparison to the MET-5A 
cells (Table 1). This is the first time the effects of different 
mesothelioma cell sub-types on VOC profiles has been 
reported. Present results show that biphasic and epithelioid 
cell types can be distinguished in vitro, with further clinical 
work required to determine how this relationship occurs in 
vivo.
Several compounds were identified at a significantly 
increased level in the headspace of the mesothelioma cell lines 
compared to the non-malignant control (Table 1). Of these 
compounds, ethyl propionate, 2-ethyl-1-hexanol and 
dodecane are present on the Volatilome Database [19], 
indicating that they have previously been reported to be 
present in human breath. 2-ethyl-1-hexanol is the only 
compound that was significantly increased in both MSTO-
211H and NCI-H28 cell lines (Table 1). Previously, 2-ethyl-
1-hexanol was used statistically to differentiate MM patients 
from those exposed to a similar level of asbestos without 
mesothelioma development [12], as well as distinguishing 
MM patients from healthy controls [13]. The correlation 
between previous in vivo results and the current in vitro study 
suggest that 2-ethyl-1-hexanol is an endogenous VOC 
released directly from MM cells. Previous studies have also 
found that 2-ethyl-1-hexanol is a compound that has been 
commonly associated with other malignancies including lung 
[20], prostate [21] and colorectal cancer [22]. Significant 
differences in 2-ethyl-1-hexanol levels have been reported in 
urine [21], blood [22], pleural effusions derived from cancer 
patients [20] and released from in vitro tumour cell lines [14]. 
Recently, 2-ethyl-1-hexanol was found to be present in the 
sweat of lung, prostate, gastric, kidney, head and neck cancer 
patients but absent from healthy controls [23].
Dodecane is also a compound that has been identified in 
MM breath analysis literature, having previously been used in 
the discrimination between MM patients, asbestos exposed 
and healthy controls [11]. Again, this compound does not 
appear to be exclusively associated with mesothelioma. Using 
SPME, dodecane was found to be increased in cell lines 
derived from haematological malignancies with comparison 
to media-only controls [24]. Dodecane has also been identified 
in studies analysing cancer patient exhaled breath samples. 
Among other VOCs, dodecane was highlighted as a potential 
biomarker for oral squamous cell carcinoma [25]. In lung 
cancer dodecane has been suggested as a potential diagnostic 
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biomarker [26, 27], particularly useful in identifying 
adenocarcinoma patients harbouring an epidermal growth 
factor receptor (EGFR) mutation [26]. Furthermore, dodecane 
was found at significantly increased levels in exhaled breath 
samples obtained from colorectal cancer patients with 
comparison to healthy controls [28].
The identification of altered 2-ethyl-1-hexanol and 
dodecane levels across a range of malignancies and biological 
matrices suggest that these are compounds that are 
ubiquitously associated with cancer or a specific cancer-
related process. The production of reactive oxygen species 
(ROS) leading to an increase of oxidative stress is thought to 
play an important role in the production of VOCs [29]. During 
prolonged periods of oxidative stress, proteins and lipids are 
particurlarly susceptible to ROS oxidative attack, leading to 
lipid peroxidation and the production of VOCs [29]. An 
increase in ROS and oxidative stress is an important process 
in malignant tumourigenesis - particularly within MM [13]. 
Inhalation of asbestos fibres leads to rounds of frustrated 
phagocytosis and unresolved oxidative stress, creating an 
environment with high levels of ROS [30]. Due to the 
biopersistence of these fibres [30], it is likely that high levels 
of oxidative stress are maintained well into malignancy, with 
ROS causing damage to phospholipids, proteins and other 
macromolecules leading to the production of VOCs [13]. 
Within MM it has been speculated that an increased 
concentration of ROS could produce a high level of oxidated 
organic species [13]. Alkanes, such as dodecane, could arise 
from lipid peroxidation, with further metabolism of alkanes 
leading to alcohols such as 2-ethyl-1-hexanol [13]. This is 
reflected in the current study, with the two MM cell lines 
showing increases in these VOCs compared to the non-
malignant control cell line, MET-5A. These results can be 
expanded further using the current in vitro system with 
experiments exploring the effects of ROS on VOC profiles. 
Inducing oxidative stress in a non-malignant cell line mimics 
what occurs during tumourigenesis and allows specific VOCs 
to be pinpointed to a particular biological process. 
The identification of compounds across multiple 
malignancies is also a good example of how a single 
compound on its own lacks the specificity required to 
diagnose mesothelioma or any other cancer effectively. The 
range and variety of VOCs already identified thus far is vast. 
The considerable amount of compounds exhaled in a single 
breath means that crossover of specific VOCs between 
different pathologies is highly probable. It is therefore much 
more likely that a breath test in clinical practice would rely on 
the identification of multiple VOC signals, with changes in 
levels and patterns of compounds indicative of a disease, 
rather than the presence of a single compound. In contrast to 
2-ethyl-1-hexanol and dodecane, this is the first time ethyl 
propionate and cyclohexanol have been reported to be 
associated with MM. Despite this, it is encouraging that 2-
ethyl-1-hexanol and dodecane were associated with MM in 
breath and also at the cell line level, highlighting these two 
compounds as important targets that warrant further 
investigation.
4.1 Conclusion
MM breath analysis is still in its early stages - previous 
studies have provided a proof of concept for the identification 
of MM patients based on VOCs in exhaled breath. The current 
study aimed to identify VOCs directly from MM cells, in order 
to provide an in vitro model of this disease. 2-ethyl-1-hexanol 
and dodecane were identified, correlating with the previous 
literature. As well as this, an initial proof of concept for the 
distinction between epithelioid and biphasic MM sub-types 
using VOC analysis was shown. This pilot study is the first 
step in the development of in vitro MM VOC analysis. The 
use of cell lines allows for subesequent experiments that 
would not be possible with patient breath samples, targeting 
the biological pathways behind these compounds. It unclear 
what a diagnostic breath test will look like in clinical practice, 
but this field of research has the potential to revolutionise 
mesothelioma diagnosis. It is vital that MM breath analysis 
research of all levels continues. 
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